Abstract:Objectives: The expression of serum free light chain (FLC) is abnormal in various diseases, but its role in lung cancer remains unclear. This study aims to investigate the expression and diagnostic value of serum FLC in lung cancer. Methods: A total of 80 lung cancer patients treated at Xiangdong Hospital, Hunan Normal University from January to December 2021 were selected as the lung cancer group. Another 80 healthy individuals undergoing routine physical examinations during the same period were chosen as the control group. General information and serum κFLC and λFLC levels were collected for all subjects. Clinical indicators such as serum carcinoembryonic antigen (CEA), cytokeratin fragment antigen 21-1 (CYFRA21-1) levels, tumor diameter, histological type, TNM stage, and lymph node metastasis status were recorded for lung cancer patients. The expression levels of serum FLC [κFLC, λFLC, and FLC (κ+λ)] were compared between the lung cancer group and the control group. Lung cancer patients were grouped based on gender, age, smoking history, tumor diameter, TNM stage, histological type, and lymph node metastasis to compare differences in serum κFLC and λFLC levels. Receiver operating characteristic (ROC) curves were used to evaluate the diagnostic value of serum FLC alone and in combination with other indicators in lung cancer. Results: The expression levels of serum FLC (κ+λ) and κFLC were significantly higher in the lung cancer group than those in the control group (both P<0.001), while there was no significant difference in serum λFLC levels between the 2 groups (P>0.05). There were no significant differences in serum κFLC levels among lung cancer patients with different tumor diameters, histological types, or TNM stages (all P>0.05); however, serum κFLC levels were higher in lung cancer patients with lymph node metastasis than in those without, with statistical significance (P=0.033). There were no significant differences in serum λFLC levels based on tumor diameter or histological type (both P>0.05), but serum λFLC levels were higher in stage III+IV and lymph node metastatic lung cancer patients compared to stage I+II and non-metastatic patients, with statistical significance (P=0.033 and P=0.019, respectively). The area under the curve (AUC) for κFLC and CEA in diagnosing lung cancer showed no significant difference (P=0.333). The combination of κFLC+CYFRA21-1 had the highest diagnostic efficacy (AUC=0.875) and sensitivity (71.3%). The AUC for the combined diagnosis of κFLC+λFLC+CEA+CYFRA21-1 was 0.915 (95% CI 0.860 to 0.953, P<0.001). Conclusions: Serum FLC is highly expressed in lung cancer and is associated with its invasion and metastasis. Serum FLC, particularly κFLC, has diagnostic value for lung cancer, and the combined detection of FLC, CEA, and CYFRA21-1 offers the best diagnostic efficacy.

[Expression and diagnosis value of Fascin in non-small cell lung cancer patients]

[Expression of Fascin and Cytokeratin 14 in Esophageal Squamous Cell Carcinoma].

Expression of Fascin-1 and its diagnostic value in liver cancer

Expression of Fascin in Esophageal Squamous Cell Carcinoma by Tissue Array Analysis

[Expression of Fas, Fas Ligand, Fas-associated Death Domain Protein, Caspase 8 and Mutant P53 Protein in Esophageal Squamous Cell Carcinoma].

Expression of fascin in oral and oropharyngeal squamous cell carcinomas has prognostic significance ? a tissue microarray study of 129 cases

Expression of Fas/Fasl Gene Protein and Its Chinical Significance in Human Non-small Cell Lung Cancer

Expression and clinical study of vascular endothelial growth factor and its receptors FLT-1, FLK-1/KDR in non-small cell lung cancer

Expression and diagnostic value of serum free light chain in lung cancer

[The Correlation Between DNA Content and Fas Antigen in Non-Small Cell Lung Cancer].

Clinical significance of CEA and CK20 expression in exfoliated cells by fiberoptic bronchoscopy brushing

Expression and clinical significance of ezrin in non--small-cell lung cancer.

High fascin-1 expression in colorectal cancer identifies patients at high risk for early disease recurrence and associated mortality

Clinical significance of the expression of alpha-fetoprotein receptor in human non small cell lung cancer

[Serum Levels of Endostatin and VEGF in Non-Small Cell Lung Cancer Patients and the Relationship with the Clinical Pathophysiological Characteristics].

Cmar_a_246566 2767..2775

The Diagnostic Value of Detecting Serum Sulfate Glycosaminoglycan Fragments in Non-small Cell Lung Cancer

Involvement of CYR61 and CTGF in the Fascin-Mediated Proliferation and Invasiveness of Esophageal Squamous Cell Carcinomas Cells.

Serum Splicing Factor Proline- and Glutamine-Rich Is a Diagnostic Marker for Non-Small-Cell Lung Cancer and Other Solid Cancers

EXPRESSION OF VASCULAR ENDOTHELIAL GROWTH FACTOR AND BASIC FIBROBLAST GROWTH FACTOR IN HUMAN NON-SMALL CELL LUNG CANCER AND THEIR CLINICAL SIGNIFICANCE

Fascin Inhibitor NP-G2-044 Decreases Cell Metastasis and Increases Overall Survival of Mice-Bearing Lung Cancers